108
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cancer is a leading cause of death worldwide. Currently available therapies are inadequate and spur demand for improved technologies. Rapid growth in nanotechnology towards the development of nanomedicine products holds great promise to improve therapeutic strategies against cancer. Nanomedicine products represent an opportunity to achieve sophisticated targeting strategies and multi-functionality. They can improve the pharmacokinetic and pharmacodynamic profiles of conventional therapeutics and may thus optimize the efficacy of existing anti-cancer compounds. In this review, we discuss state-of-the-art nanoparticles and targeted systems that have been investigated in clinical studies. We emphasize the challenges faced in using nanomedicine products and translating them from a preclinical level to the clinical setting. Additionally, we cover aspects of nanocarrier engineering that may open up new opportunities for nanomedicine products in the clinic.

          Related collections

          Author and article information

          Journal
          J Control Release
          Journal of controlled release : official journal of the Controlled Release Society
          1873-4995
          0168-3659
          Feb 28 2015
          : 200
          Affiliations
          [1 ] Division of Oncology, Department of Internal Medicine, University Hospital of Basel, Basel, Switzerland.
          [2 ] Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
          [3 ] Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
          [4 ] Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. Electronic address: joerg.huwyler@unibas.ch.
          Article
          S0168-3659(14)00827-X
          10.1016/j.jconrel.2014.12.030
          25545217
          908f0c57-e79a-4309-a1e0-3fb00c625500
          Copyright © 2014 Elsevier B.V. All rights reserved.
          History

          Cancer nanomedicine,Clinical trials,Drug delivery,Liposome,Nanoparticle,Targeting

          Comments

          Comment on this article